Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Sarcoma 43Melanoma 19Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Glioblastoma 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Gliosarcoma 7Lung Neoplasms 6Histiocytoma, Malignant Fibrous 6Carcinoma, Renal Cell 6Osteosarcoma 5Liposarcoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Sarcoma, Synovial 4Sarcoma, Kaposi 4Neurofibrosarcoma 4Lymphoma 4Hemangiosarcoma 4Carcinoma, Merkel Cell 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Recurrence 3

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × pembrolizumab × Sarcoma × Clear all
NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡